Citations

Mayo Clinic

Showing 10 of 108551 citations.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Ruella, Marco , Kenderian, Saad S. , Shestova, Olga, Fraietta, Joseph A. , Qayyum, Sohail , Zhang, Qian , Liu, Xiaobin , Nuñez-Cruz, Selene , Klichinsky, Michael , Kawalekar, Omkar U. , Milone, Michael C. , Mato, Anthony R. , Kalos, Michael , June, Carl H. , Gill, Saar , Wasik, Mariusz A. , Maus, Marcela V , Lacey, Simon Francis , Schuster, Stephen J. , Kenderian, Saad Sirop , Ruella, Marco

Clinical Cancer Research | January 27, 2016 | Volume: 22 | Issue: 11 | Pages: 2684-2696

10.1158/1078-0432.ccr-15-1527 | PMID 26819453 Get It

Abstract Purpose: Responses to therapy with chimeric antigen receptor T cells recognizing CD19 (CART19, CTL019) may vary by histology. Mantle cell lymphoma (MCL) represents a B-cell malignancy that remains incurable despite novel therapies such as the BTK inhibitor ibrutinib, and where data from CTL019 therapy are scant. Using MCL as a model, we sought to build upon the outcomes from CTL019 and from ibrutinib therapy by combining these in a rational manner. Experimental Design: MCL cell lines and primary MCL samples were combined with autologous or normal donor-derived anti-CD19 CAR T cells along with ibrutinib. The effect of the combination was studied in vitro and in mouse xenograft models. Results: MCL cells strongly activated multiple CTL019 effector functions, and MCL killing by CTL019 was further enhanced in the presence of ibrutinib. In a xenograft MCL model, we showed superior disease control in the CTL019- as compared with ibrutinib-treated mice (median survival not reached vs. 95 days, P < 0.005) but most mice receiving CTL019 monotherapy eventually relapsed. Therefore, we added ibrutinib to CTL019 and showed that 80% to 100% of mice in the CTL019 + ibrutinib arm and 0% to 20% of mice in the CTL019 arm, respectively, remained in long-term remission (P < 0.05). Conclusions: Combining CTL019 with ibrutinib represents a rational way to incorporate two of the most recent therapies in MCL. Our findings pave the way to a two-pronged therapeutic strategy in patients with MCL and other types of B-cell lymphoma. Clin Cancer Res; 22(11); 2684–96. ©2016 AACR.
Hyperglycemia During the Immediate Period Following Liver Transplantation
Werner, K. Tuesday , Castro, Janna C. , Carey, Elizabeth J. , Chakkera, Harini A. , Mackey, Patricia A, Cook, Curtiss B. , Mackey, Patricia , Chakkera, Harini A , Werner, Kristina Tuesday

Future Science OA | January 27, 2016 | Volume: 2 | Issue: 1 | Pages: No page available

10.4155/fsoa-2015-0010 | PMID 28031946 Get It

Human Imaging With Photon Counting–Based Computed Tomography at Clinical Dose Levels
Gutjahr, Ralf , Halaweish, Ahmed F., Yu, Zhicong , Yu, Lifeng , Li, Zhoubo , Jorgensen, Steven M., Ritman, Erik L., Kappler, S. , Leng, Shuai , Yu, Lifeng , McCollough, Cynthia H.

Investigative Radiology | January 27, 2016 | Volume: 51 | Issue: 7 | Pages: 421-429

10.1097/rli.0000000000000251 | PMID 26818529 Get It

Objectives The purpose of this work was to measure and compare the iodine contrast-to-noise ratio (CNR) between a commercial energy-integrating detector (EID) computed tomography (CT) system and a photon-counting detector (PCD) CT scanner capable of human imaging at clinical dose rates, as well as to determine clinical feasibility using human cadavers. Materials and Methods A research dual-source PCD-CT scanner was used, where the “A” tube/detector subsystem used an EID and the “B” tube/detector subsystem used a PCD. Iodine CNR was measured in 4 anthropomorphic phantoms, simulating 4 patient sizes, at 4 tube potential settings. After biospecimen committee approval, PCD scans were performed on a fresh-frozen human head and a whole-body cadaver using clinical dose rates. Scans were repeated using the EID and identical parameters, and qualitative side-by-side comparisons were performed. Results For the same photon fluence, phantom measurements demonstrated a mean increase in CNR of 11%, 23%, 31%, 38% for the PCD system, relative to the EID system, at 80, 100, 120, and 140 kV, respectively. Photon-counting detector CT additionally provided energy-selective imaging, where low- and high-energy images reflected the energy dependence of the iodine signal. Photon-counting detector images of cadaveric anatomy demonstrated decreased beam hardening and calcium blooming in the high-energy bin images and increased contrast in the low-energy bins images relative to the EID images. Threshold-based PCD images were qualitatively deemed equivalent in other aspects. Conclusions The evaluated research PCD-CT system was capable of clinical levels of image quality at clinical dose rates. It further provided improved CNR relative to state-of-the-art EID-CT. The energy-selective bin images provide further opportunity for dual-energy and multienergy analyses.
Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release
Arsoy, Diren , Riester, Scott M. , Wijnen, André J. van , Morrey, B.F. , Barlow, Jonathan D. , Morrey, Mark E. , Hartzler, Robert U. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , van Wijnen, Andre J

Bone & Joint Research | January 27, 2016 | Volume: 5 | Issue: 1 | Pages: 11-17

10.1302/2046-3758.51.2000593 | PMID 26813567 Get It

Aims Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (sd) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties. Cite this article: M. P. Abdel. Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis. Bone Joint Res 2016;5:11–17. doi: 10.1302/2046-3758.51.2000593
TDP‐43 in the olfactory bulb in Alzheimer's disease
Josephs, Keith A. , Dickson, Dennis W.

Neuropathology and Applied Neurobiology | January 26, 2016 | Volume: 42 | Issue: 4 | Pages: 390-393

10.1111/nan.12309 | PMID 26810591 Get It

Modeling GATAD1-Associated Dilated Cardiomyopathy in Adult Zebrafish
Yang, Jingchun , Shah, Sahrish, Olson, Timothy M. , Xu, Xiaolei

Journal of Cardiovascular Development and Disease | January 26, 2016 | Volume: 3 | Issue: 1 | Pages: 6

10.3390/jcdd3010006 | PMID 28955713 Get It

Animal models have played a critical role in validating human dilated cardiomyopathy (DCM) genes, particularly those that implicate novel mechanisms for heart failure. However, the disease phenotype may be delayed due to age-dependent penetrance. For this reason, we generated an adult zebrafish model, which is a simpler vertebrate model with higher throughput than rodents. Specifically, we studied the zebrafish homologue of GATAD1, a recently identified gene for adult-onset autosomal recessive DCM. We showed cardiac expression of gatad1 transcripts, by whole mount in situ hybridization in zebrafish embryos, and demonstrated nuclear and sarcomeric I-band subcellular localization of Gatad1 protein in cardiomyocytes, by injecting a Tol2 plasmid encoding fluorescently-tagged Gatad1. We next generated gatad1 knock-out fish lines by TALEN technology and a transgenic fish line that expresses the human DCM GATAD1-S102P mutation in cardiomyocytes. Under stress conditions, longitudinal studies uncovered heart failure (HF)-like phenotypes in stable KO mutants and a tendency toward HF phenotypes in transgenic lines. Based on these efforts of studying a gene-based inherited cardiomyopathy model, we discuss the strengths and bottlenecks of adult zebrafish as a new vertebrate model for assessing candidate cardiomyopathy genes.
Biopsy‐proven pulmonary capillaritis: A retrospective study of aetiologies including an in‐depth look at isolated pulmonary capillaritis
Thompson, Gwen , Klecka, Mary E., Roden, Anja C. , Cartin‐Ceba, Rodrigo , Klecka, Mary, Specks, Ulrich

Respirology | January 26, 2016 | Volume: 21 | Issue: 4 | Pages: 734-738

10.1111/resp.12738 | PMID 26809449 Get It

AbstractBackground and objectivePulmonary capillaritis is generally secondary to a systemic autoimmune process. Little is known regarding other causes of pulmonary capillaritis, particularly isolated pulmonary capillaritis (IPC). IPC is defined as pulmonary capillaritis in the absence of evidence of a systemic disease. We aim to describe the aetiology of biopsy‐proven pulmonary capillaritis to add to the existing knowledge on aetiologies of pulmonary capillaritis and provide a more detailed description of IPC cases.MethodsA retrospective cohort of biopsy‐proven pulmonary capillaritis was conducted at the Mayo Clinic, Rochester over a 17‐year period. Histologic slides were re‐reviewed by a lung pathologist. Medical records were reviewed to identify a possible aetiology of the pulmonary capillaritis. A subset analysis of patients identified with IPC was then performed.ResultsThirty‐six cases of biopsy‐proven pulmonary capillaritis were identified. The majority of cases were secondary to a systemic autoimmune disease, most commonly granulomatosis with polyangiitis. There were four cases of IPC in this cohort. Median follow‐up was 116.5 months with no evidence of systemic disease development. No risk factors for IPC were identified. All patients presented sub‐acutely with haemoptysis and diffuse alveolar haemorrhage with a delay in diagnosis. After initiation of immunosuppression, most patients obtained remission with a benign clinical course.ConclusionPulmonary capillaritis is most commonly secondary to systemic autoimmune disorders, predominantly ANCA‐associated vasculitis. IPC is a rare form of pulmonary capillaritis with very few cases described in the literature, the availability of effective treatment makes this rare disease important to recognize.
Mechanism of aortic root dilation and cardiovascular function in tetralogy of Fallot
Seki, Mitsuru , Kuwata, Seiko, Kurishima, Clara, Nakagawa, Ryo , Sugimoto, Masaya, Saiki, Hirofumi , Iwamoto, Yoichi, Ishido, Hirotaka , Masutani, Satoshi , Inuzuka, Ryo , Senzaki, Hideaki

Pediatrics International | January 26, 2016 | Volume: 58 | Issue: 5 | Pages: 323-330

10.1111/ped.12932 | PMID 26809655 Get It

AbstractThe aortic root dilation in tetralogy of Fallot (TOF) is a long‐term clinical problem, because a severely dilated aorta can lead to aortic regurgitation, dissection, or rupture, which can be fatal, necessitating surgical intervention. The details of the mechanism of aortic root dilation, however, are unclear. We have shown that aortic stiffness is increased in patients with repaired TOF, and may mirror the histological abnormality of elastic fiber disruption and matrix expansion. This aortic stiffness is related closely to the aortic dilation, indicating that aortic stiffness may be a predictor of outcome of aortic dilation. Furthermore, the aortic volume overload is a very important determinant of aortic diameter in TOF patients before corrective surgery. In addition, a chromosomal abnormality and the transforming growth factor‐β signaling pathway, a major contributor to aortic dilation in Marfan syndrome, also affect this mechanism. In this way, aortic dilation in TOF patients is suggested to be a multifactorial disorder. The aim of this review was therefore to clarify the mechanism of aortic dilation in TOF, focusing on recent research findings. Studies linking histopathology, mechanical properties, molecular/cellular physiology, and clinical manifestations of aortic dilation facilitate appropriate treatment intervention and improvement of long‐term prognosis of TOF.
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
Renfro, Lindsay A. , Allegra, Carmen J. , André, Thierry , Gramont, Aimery de , Haller, Daniel G. , Yothers, Greg , Shah, Manish A, de Gramont, Aimery, Schmoll, Hans‐Joachim , Shah, Manish A , Alberts, Steven R. , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Journal of Clinical Oncology | January 26, 2016 | Volume: 34 | Issue: 8 | Pages: 843-853

10.1200/jco.2015.63.0558 | PMID 26811529 Get It

Purpose Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. Patients and Methods A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Results Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. Conclusions These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.
Uncovering Neuroanatomical Networks Responsible for Abnormal Eating Behavior in Frontotemporal Dementia
Whitwell, Jennifer L.

JAMA Neurology | January 26, 2016 | Volume: 73 | Issue: 3 | Pages: 267

10.1001/jamaneurol.2015.4496 | PMID 26810266 Get It